These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity. Agren A; Wiman B; Schulman S Blood Coagul Fibrinolysis; 2007 Oct; 18(7):657-60. PubMed ID: 17890953 [TBL] [Abstract][Full Text] [Related]
10. Rapid purification of a high-affinity plasminogen activator from human blood plasma by specific adsorption on fibrin/Celite. Husain SS; Lipinski B; Greuwich V Proc Natl Acad Sci U S A; 1981 Jul; 78(7):4265-9. PubMed ID: 6270665 [TBL] [Abstract][Full Text] [Related]
11. Releasing the Brakes on the Fibrinolytic System in Pulmonary Emboli: Unique Effects of Plasminogen Activation and α2-Antiplasmin Inactivation. Singh S; Houng A; Reed GL Circulation; 2017 Mar; 135(11):1011-1020. PubMed ID: 28028005 [TBL] [Abstract][Full Text] [Related]
12. [Tissue type plasminogen activator and its inhibition in blood of patients operated on for prostatic carcinoma]. Iwan-Zietek I; Zietek Z; Kotschy M; Rość D; Tyloch F Pol Tyg Lek; 1996 Feb; 51(6-9):91-3. PubMed ID: 8756741 [TBL] [Abstract][Full Text] [Related]
13. [Releasing of plasminogen-activator from the kidney to the blood (author's transl)]. Nakata A; Hagita M; Okamoto U Nihon Seirigaku Zasshi; 1978 Nov; 40(11):419-26. PubMed ID: 155161 [TBL] [Abstract][Full Text] [Related]
14. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration. Collen D; Stassen JM; Verstraete M J Clin Invest; 1983 Feb; 71(2):368-76. PubMed ID: 6681615 [TBL] [Abstract][Full Text] [Related]
15. The interaction of streptokinase.plasminogen activator complex, tissue-type plasminogen activator, urokinase and their acylated derivatives with fibrin and cyanogen bromide digest of fibrinogen. Relationship to fibrinolytic potency in vitro. Cassels R; Fears R; Smith RA Biochem J; 1987 Oct; 247(2):395-400. PubMed ID: 3122725 [TBL] [Abstract][Full Text] [Related]
16. Inherited fibrinolytic disorder due to an enhanced plasminogen activator level. Aznar J; Estellés A; Vila V; Regañón E; España F; Villa P Thromb Haemost; 1984 Oct; 52(2):196-200. PubMed ID: 6543037 [TBL] [Abstract][Full Text] [Related]
17. Periorbital ecchymoses as the initial sign in multiple myeloma. Loo H; Forman WB; Levine MR; Crum ED; Rassiga AL Ann Ophthalmol; 1982 Nov; 14(11):1066-8. PubMed ID: 7181338 [TBL] [Abstract][Full Text] [Related]
18. Extrinsic plasminogen activator: a new principle in fibrinolysis. Lijnen HR Behring Inst Mitt; 1983 Aug; (73):43-55. PubMed ID: 6236789 [TBL] [Abstract][Full Text] [Related]